BOLT
Income statement / Annual
Last year (2025), Bolt Biotherapeutics Inc's total revenue was $7.70 M,
an increase of 0.07% from the previous year.
In 2025, Bolt Biotherapeutics Inc's net income was -$33.38 M.
See Bolt Biotherapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$7.70 M |
$7.69 M |
$7.88 M |
$5.73 M |
$1.26 M |
$231.00 K |
$215.00 K |
$0.00 |
| Cost of Revenue |
$1.49 M
|
$0.00
|
$61.54 M
|
$73.12 M
|
$75.66 M
|
$40.36 M
|
$0.00
|
$302.00 K
|
| Gross Profit |
$6.20 M
|
$7.69 M
|
-$53.67 M
|
-$67.39 M
|
-$74.40 M
|
-$40.13 M
|
$215.00 K
|
-$302.00 K
|
| Gross Profit Ratio |
0.81
|
1
|
-6.81
|
-11.76
|
-59.04
|
-173.71
|
1
|
0
|
| Research and Development Expenses |
$28.53 M
|
$57.47 M
|
$61.54 M
|
$73.12 M
|
$75.66 M
|
$40.36 M
|
$26.00 M
|
$9.42 M
|
| General & Administrative Expenses |
$13.80 M
|
$18.46 M
|
$22.53 M
|
$22.93 M
|
$18.39 M
|
$9.06 M
|
$5.18 M
|
$2.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.80 M
|
$18.46 M
|
$22.53 M
|
$22.93 M
|
$18.39 M
|
$9.06 M
|
$5.18 M
|
$2.21 M
|
| Other Expenses |
-$1.49 M
|
$4.81 M
|
-$61.54 M
|
-$73.12 M
|
-$75.66 M
|
-$40.36 M
|
$0.00
|
-$153.00 K
|
| Operating Expenses |
$40.84 M
|
$80.74 M
|
$22.53 M
|
$22.93 M
|
$18.39 M
|
$9.06 M
|
$31.18 M
|
$11.63 M
|
| Cost And Expenses |
$42.33 M
|
$80.74 M
|
$84.07 M
|
$96.05 M
|
$94.05 M
|
$49.41 M
|
$31.18 M
|
$11.63 M
|
| Interest Income |
$2.50 M
|
$5.26 M
|
$7.00 M
|
$2.22 M
|
$281.00 K
|
$199.00 K
|
$524.00 K
|
$193.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.49 M
|
$1.78 M
|
$1.85 M
|
$1.67 M
|
$1.19 M
|
$611.00 K
|
$335.00 K
|
$302.00 K
|
| EBITDA |
-$33.14 M |
-$66.46 M |
-$74.34 M |
-$88.66 M |
-$91.60 M |
-$48.57 M |
-$30.63 M |
-$11.33 M |
| EBITDA Ratio |
-4.31
|
-8.64
|
-9.44
|
-15.47
|
-72.69
|
-210.26
|
-142.48
|
0
|
| Operating Income Ratio |
-4.5
|
-9.5
|
-9.67
|
-15.77
|
-73.64
|
-212.91
|
-144.04
|
0
|
| Total Other Income/Expenses Net |
$1.26 M
|
$9.93 M
|
$7.00 M
|
$2.22 M
|
-$5.80 M
|
-$11.55 M
|
$482.00 K
|
$40.00 K
|
| Income Before Tax |
-$33.38 M
|
-$63.12 M
|
-$69.20 M
|
-$88.10 M
|
-$98.59 M
|
-$60.73 M
|
-$30.49 M
|
-$11.59 M
|
| Income Before Tax Ratio |
-4.34
|
-8.21
|
-8.79
|
-15.38
|
-78.25
|
-262.89
|
-141.8
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$40.00 K
|
| Net Income |
-$33.38 M
|
-$63.12 M
|
-$69.20 M
|
-$88.10 M
|
-$98.59 M
|
-$60.73 M
|
-$30.49 M
|
-$11.59 M
|
| Net Income Ratio |
-4.34
|
-8.21
|
-8.79
|
-15.38
|
-78.25
|
-262.89
|
-141.8
|
0
|
| EPS |
-17.85 |
-1.65 |
-1.83 |
-2.3 |
-2.79 |
-1.99 |
-3.75 |
-5.96 |
| EPS Diluted |
-17.85 |
-1.65 |
-1.83 |
-2.3 |
-2.79 |
-1.99 |
-3.75 |
-5.96 |
| Weighted Average Shares Out |
$1.87 M
|
$38.18 M
|
$37.81 M
|
$37.36 M
|
$37.40 M
|
$36.25 M
|
$8.01 M
|
$1.94 M
|
| Weighted Average Shares Out Diluted |
$1.87 M
|
$38.18 M
|
$37.81 M
|
$37.36 M
|
$37.40 M
|
$36.25 M
|
$8.01 M
|
$1.94 M
|
| Link |
|
|
|
|
|
|
|
|
